What does agomelatine bring to treatment of depression?an up-to-date review
Küçük Resim Yok
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Istanbul Universitesi
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
In this article literature related to the promises of agomelatine, an antidepressant with melatonergic MT-1 and MT- 2 receptor agonism and seratoninergic 5-HT2c receptor antagonism in the context of depression treatment is reviewed. Although the results of studies on the efficacy of agomelatine are contrary, it can be stressed that the efficacy of agomelatine should be at least similar to widely used antidepressants. Furthermore the favorable effect of agomelatine on sleep and the early onset of efficacy should contribute to the outcome of therapy. The favorable effect of agomelatine on the circadian rhythm which has influence on substantial biological systems like sleepwake cycle, endocrine hormone secretion and body temperature appears to be interesting. Somnolence should be noted as a more frequent adverse event of agomelatine than other antidepressants. Furthermore the absence of weight gain and sexual adverse events should influence the adherence to therapy. Liver enzyme elevations can emerge during agomelatine therapy. Abrupt discontinuation of agomelatine does not appear to bring about evident discontinuation symptoms.
Açıklama
Anahtar Kelimeler
Agomelatine, Depression, Melatonin
Kaynak
Yeni Symposium
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
51
Sayı
3
